Imexhs Ltd · ASX:IME
Imexhs — Shareholder Meeting (May 2022)
32 slides from Imexhs's shareholder meeting presentation, May 19, 2022
Slide 1: Annual General Meeting
Annual General Meeting 19 May 2022
Slide 2: Board of Directors
Board of Directors Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO & Managing Chairman Director Director Director Director IMEXHS LTD (ASX:IME) | AGM May 19 2022 2
Slide 3: Registration & Voting
Registration & Voting 1. Log in or register at: 2. Click view and register 3. Record your vote. Once https://investor.automic.com.au/#/home your attendance for the you confirm it is lodged and meeting final To contact support: Call 1300 816 159 or open live chat from the Investor Portal
Slide 4: Agenda
Agenda 2022 AGM 1. Introductions 2. Chairman’s Address 3. CEO’s Address 4. Business of Meeting 5. Resolutions & Proxy Vote Results 4
Slide 5: Chairman's Address
Chairman’s Address Doug Flynn
Slide 6: One Company with two businesses aimed at democratising access to medical expertise
One Company with two businesses aimed at democratising access to medical expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities AI medical imaging software and teleradiology to hospitals and solutions medical facilities 6
Slide 7: CEO's Address
CEO’s Address Dr German Arango
Slide 8: Our 10-year Journey
Our 10-year Journey Founded in Bogota, Colombia to provide access to medical technology in 2012 hard-to-reach areas 2015 Expanded into countries in Latin America such as Ecuador and Mexico 2018 Listed on the Australian Securities Exchange to expand our global presence 2019 Received FDA Clearance in
Slide 9: Expanding global footprint
Expanding global footprint Software Services 15 countries; 398 sites Colombia, Spain and 2,500+ radiologists Mexico 35 distributors in 17 33 radiology centres countries 100+ in-house radiologists 37 software development engineers 9
Slide 10: FY21 Financial Highlights
FY21 Financial Highlights Sales Revenue1 Annual Recurring EBITDA Revenue (ARR) Up 23% yoy $13.4m Up 102% yoy $20.4m vs ($1.3m) in FY20 ($3.0m) Up 34% on a constant Up 121% on a constant due to continued currency basis currency basis investment in operations Recurring Closing cash Underlying revenue
Slide 11: 2025+ Endgame
2025+ Endgame Enterprise Imaging – Single – Medical Imaging platform RIS, PACS, VNA – – Cloud Technology Results Distribution Portal – Software – Multitenant Digital Pathology – Platform – DevOps Interoperability – – Onboarding automation Teleradiology – – SaaS / PaaS Business Model Multi-Department
Slide 12: 5-year Strategy Framework
5-year Strategy Framework 2025+ Harvesting 10% Resource Allocation 2024 | 2025 Growing (Product Offering) IMEXHS Cloud 20% Resource Allocation • Single Unified Medical Imaging Single Software Software Platform Platform • SaaS/PaaS architecture (Base + Extensions) • Other ologies Digital pathology Me
Slide 13: Current Trading
Current Trading • Q1 FY22 revenue of $4.7m, up 89% vs pcp (88% on a constant currency basis) and up 39% excluding RIMAB • Underlying Q1 FY22 EBITDA loss of $0.2m, up $0.6m vs pcp of loss of $0.8m • Annual Recurring Revenue (ARR) of $21.5m, up 95% vs pcp (94% on a cc basis) • IMEXHS Cloud (formerly A
Slide 14: Strong growth in ARR continues
Strong growth in ARR continues Q1 2017 2018 2019 2020 2021 FY22 +95% pcp (+94% 25 on a constant currency basis) 20 A$ Millions 15 10 5 0 2017 2018 2019 2020 2021 Q1 FY22 Spot Not Yet Billing Constant Currency Not Yet Billing ARR as at 31 March 2022 • $21.5m = $14.1m from Radiology Services and $7.4m
Slide 15: FY22 Outlook
FY22 Outlook Initiatives to reach profitability Global expansion – fuelled by and cashflow breakeven while recent Neusoft Medical continuing to keep the integrity of partnership, entry into Thailand our 5-year strategic framework and greater presence in the US, Australia and the UK • Cost savings th
Slide 16: Business of Meeting
ime «Hs Business of Meeting
Slide 17: Resolutions & Proxy Vote Results
Resolutions & Proxy Vote Results
Slide 18: Financial Report
Financial Report To receive the financial report of the Company and the reports of the Directors and of the Auditors for the financial year ended 31 December 2021. Q&A
Slide 19: 1: Remuneration Report
Resolution 1: Remuneration Report “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 31 December 2021 as disclosed in the Company’s Annual Report be adopted.” Proxy votes For Against Open 4,655,492 25,48
Slide 20: 2: Re-election of Director
Resolution 2: Re-election of Director “That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rule 14.5, and for all other purposes, Mr Carlos Palacio, a Director, retires by rotation, and being eligible, is re-elected as a Director of the Company.” Proxy votes For Against Open 8,2
Slide 21: 3: Grant of Options to the Chief Executive Officer
Resolution 3: Grant of Options to the Chief Executive Officer “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 73,393 Options to the Managing Director & CEO, Dr German Arango, under the Plan on the terms and conditions set out in the Exp
Slide 22: 4: Grant of Options to Non-Executive Director Mr Damian Banks
Resolution 4: Grant of Options to Non-Executive Director Mr Damian Banks “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 20,044 Options to Non-Executive Director, Mr Damian Banks, under the Plan on the terms and conditions set out in th
Slide 23: 5: Grant of Options to Non-Executive Director Mr Douglas Flynn
Resolution 5: Grant of Options to Non-Executive Director Mr Douglas Flynn “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 40,087 Options to Non-Executive Director, Mr Douglas Flynn, under the Plan on the terms and conditions set out in
Slide 24: 6: Grant of Options to Non-Executive Director Dr Doug Lingard
Resolution 6: Grant of Options to Non-Executive Director Dr Doug Lingard “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 20,044 Options to Non-Executive Director, Dr Doug Lingard, under the Plan on the terms and conditions set out in th
Slide 25: 7: Grant of Options to Non-Executive Director Mr Carlos Palacio
Resolution 7: Grant of Options to Non-Executive Director Mr Carlos Palacio “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 20,044 Options to Non-Executive Director, Mr Carlos Palacio, under the Plan on the terms and conditions set out i
Slide 26: 8: Issue of Shares in Lieu of Director Fees to Damian Banks
Resolution 8: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Damian Banks “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Mr Damian Banks, in lieu of the payment of certain dir
Slide 27: 9: Issue of Shares in Lieu of Director Fees to Douglas Flynn
Resolution 9: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Douglas Flynn “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Mr Douglas Flynn, in lieu of the payment of certain d
Slide 28: 10: Issue of Shares in Lieu of Director Fees to Dr Doug Lingard
Resolution 10: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Dr Doug Lingard “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Dr Doug Lingard, in lieu of the payment of certain
Slide 29: 11: Issue of Shares in Lieu of Director Fees to Carlos Palacio
Resolution 11: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Carlos Palacio “That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Mr Carlos Palacio, in lieu of the payment of certai
Slide 30: 12: Approval of 10% Share Placement Capacity
Resolution 12: Approval of 10% Share Placement Capacity "That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) (10% S
Slide 31: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 32: Annual General Meeting
Annual General Meeting 19 May 2022